Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse

Fiorentina Roviezzo, Antonietta Rossi, Elisabetta Caiazzo, Pierangelo Orlando, Maria A Riemma, Valentina M Iacono, Andrea Guarino, Armando Ialenti, Carla Cicala, Alessio Peritore, Raffaele Capasso, Vincenzo Di Marzo, Angelo A Izzo. Front Pharmacol. 2017 Dec 12;8:857.

Laboratory studyOther animals

Design

Laboratory study

Subjects

Mice sensitized with ovalbumin (OVA) to model allergic airway sensitization

Dose used in the study

PEA 10 mg/kg, given 15 minutes before each allergen exposure

Duration

Sensitization period with repeated allergen exposures

What was measured

Bronchial PEA levels, CB2 and GPR55 receptor expression, bronchial hyperreactivity, IgE, pulmonary inflammation, mast cell recruitment/degranulation and leukotriene C4

What the authors reported

OVA sensitisation lowered bronchial PEA levels and raised CB2 and GPR55 receptor expression. PEA supplementation prevented OVA-induced bronchial hyperreactivity and reduced pulmonary inflammation, mast cell recruitment and degranulation, and leukotriene C4 production, without affecting the IgE rise.

Limits of this study

A mouse model of allergic sensitization; it cannot show effect in people with asthma. Funding and conflicts not stated in the abstract.

Source

PubMed 29311913 · doi:10.3389/fphar.2017.00857

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.